Market Report, "Morocco Pharmaceuticals & Healthcare Report Q4 2014", published

As Morocco's economic conditions improve towards the end of 2014 and the rate of decline in pharmaceutical sales slows, we hold an overall positive outlook for the market over the medium - to - long term, which will be driven by the growing middle class. However, the country's inefficient regulatory environment , coupled with a weak healthcare infrastructure and poor health insurance cover , will continue to create difficult operating conditions for drugmakers, impeding the market's potential.

Headline Expenditure Projections

* Pharmaceuticals: MAD9.32bn (USD1.11bn) in 2013 to MAD9.36bn (USD1.12bn) in 2014; +0.4% in local currency terms and +0.8% in US dollar terms.
* Healthcare: MAD57.78bn (USD6.88bn) in 2013 to MAD62.66bn (USD7.49bn) in 2014; +8.4% in local currency terms and +8.8% in US dollar terms. Forecast higher than in Q214 due to upward revision of historical figures for pharmaceutical market.

Full Report Details at
- http://www.fastmr.com/prod/888555_morocco_pharmaceuticals_healthcare_report_q4_2014.aspx?afid=301

Risk/Reward Rating

In our latest proprietary Pharmaceutical Risk/Reward Ratings (RRR), Morocco continues to be viewed as a moderately attractive pharmaceutical market in the Middle East and Africa (MEA) region, from a longer-term perspective. Morocco ranks 15 ^th in the region, out of the 31 countries assessed in our ratings matrix, with a score of 42.3 out of 100. The market's constraints include low per capita consumption and an underdeveloped reimbursement system, although such factors are to a degree offset by a relatively predictable operating environment.

Key Trends And Developments

In September 2014, Abderrahmane Maâroufi, director of the Epidemiology and Fight against Diseases at the health ministry, stated that Morocco had launched a preparedness and response plan for Ebola Virus Disease (EVD), reports Morocco Gazette. The plan is based on preventing the introduction of EVD and risk detection and analysis. The health ministry has implemented control measures that target air traffic and ports that receive cargo from West Africa....

The Morocco Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Morocco Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Moroccan pharmaceutical and healthcare industry.

Key Benefits

* Benchmark BMI's independent pharmaceutical and healthcare industry forecasts for Morocco to test other views - a key input for successful budgeting and strategic business planning in the Moroccan pharmaceutical and healthcare market.

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

You may also be interested in these related reports:

- South Korea Pharmaceuticals & Healthcare Report Q4 2014
- Sweden Pharmaceuticals & Healthcare Report Q4 2014
- Greece Pharmaceuticals & Healthcare Report Q4 2014
- Saudi Arabia Pharmaceuticals & Healthcare Report Q4 2014
- Kenya Pharmaceuticals & Healthcare Report Q4 2014